

# Cell-Associated Flagella Enhance the Protection Conferred by Mucosally-Administered Attenuated *Salmonella* Paratyphi A Vaccines

Orit Gat<sup>1,2</sup>, James E. Galen<sup>1,2\*</sup>, Sharon Tennant<sup>1,2</sup>, Raphael Simon<sup>1,2</sup>, William C. Blackwelder<sup>1,2</sup>, David J. Silverman<sup>3</sup>, Marcela F. Pasetti<sup>1,4</sup>, Myron M. Levine<sup>1,2,4</sup>

**1** Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America, **2** Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, United States of America, **3** Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America, **4** Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, United States of America

## Abstract

**Background:** Antibiotic-resistant *Salmonella enterica* serovar Paratyphi A, the agent of paratyphoid A fever, poses an emerging public health dilemma in endemic areas of Asia and among travelers, as there is no licensed vaccine. Integral to our efforts to develop a *S. Paratyphi A* vaccine, we addressed the role of flagella as a potential protective antigen by comparing cell-associated flagella with exported flagellin subunits expressed by attenuated strains.

**Methodology:** *S. Paratyphi A* strain ATCC 9150 was first deleted for the chromosomal *guaBA* locus, creating CVD 1901. Further chromosomal deletions in *fliD* (CVD 1901D) or *flgK* (CVD 1901K) were then engineered, resulting in the export of unpolymerized FliC, without impairing its overall expression. The virulence of the resulting isogenic strains was examined using a novel mouse LD<sub>50</sub> model to accommodate the human-host restricted *S. Paratyphi A*. The immunogenicity of the attenuated strains was then tested using a mouse intranasal model, followed by intraperitoneal challenge with wildtype ATCC 9150.

**Results:** Mucosal (intranasal) immunization of mice with strain CVD 1901 expressing cell-associated flagella conferred superior protection (vaccine efficacy [VE], 90%) against a lethal intraperitoneal challenge, compared with the flagellin monomer-exporting mutants CVD 1901K (30% VE) or CVD 1901D (47% VE). The superior protection induced by CVD 1901 with its cell-attached flagella was associated with an increased IgG2a:IgG1 ratio of FliC-specific antibodies with enhanced opsonophagocytic capacity.

**Conclusions:** Our results clearly suggest that enhanced anti-FliC antibody-mediated clearance of *S. Paratyphi A* by phagocytic cells, induced by vaccines expressing cell-associated rather than exported FliC, might be contributing to the vaccine-induced protection from *S. Paratyphi A* challenge *in vivo*. We speculate that an excess of IgG1 anti-FliC antibodies induced by the exported FliC may compete with the IgG2a subtype and block binding to specific phagocyte Fc receptors that are critical for clearing an *S. Paratyphi A* infection.

**Citation:** Gat O, Galen JE, Tennant S, Simon R, Blackwelder WC, et al. (2011) Cell-Associated Flagella Enhance the Protection Conferred by Mucosally-Administered Attenuated *Salmonella* Paratyphi A Vaccines. *PLoS Negl Trop Dis* 5(11): e1373. doi:10.1371/journal.pntd.0001373

**Editor:** Edward T. Ryan, Massachusetts General Hospital, United States of America

**Received:** July 28, 2011; **Accepted:** September 8, 2011; **Published:** November 1, 2011

**Copyright:** © 2011 Gat et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** Funding for this study was from the Middle Atlantic RCE Program NIAID/NIH 2 U54 AI057168 grant (MML, Principal Investigator). RS was also supported by NIH T32 AI07524 Fellowship Training Program in Vaccinology (MML, Principal Investigator). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

\* E-mail: jgalen@medicine.umaryland.edu

## Introduction

Four human host-restricted *Salmonella enterica* serovars cause clinically indistinguishable typhoid (*Salmonella* Typhi) and paratyphoid (*S. Paratyphi A*, B and [uncommonly] C) fever [1]. Multiply antibiotic resistant *S. Paratyphi A* have emerged in Asia, accompanied by increased incidences of paratyphoid fever in endemic populations [2,3] and in travelers [4]. Whereas vaccines exist to prevent typhoid fever, there is no licensed vaccine to prevent *S. Paratyphi A* disease. Vaccines for preventing typhoid fever include the purified Vi capsular polysaccharide administered parenterally and attenuated Vi-negative strain Ty21a given orally

as a live vaccine [5]. Vi conjugated to recombinant exotoxin A of *Pseudomonas aeruginosa* conferred on Vietnamese children a high level of efficacy in a field trial [6,7]. Vi-based vaccines cannot protect against paratyphoid disease as *S. Paratyphi A* does not express Vi. Oral Ty21a confers moderate cross protection against *S. Paratyphi B* [8] but not *S. Paratyphi A* [9]. Despite the public health need [4], there have been few reports on modern *S. Paratyphi A* vaccine development [10,11].

Attenuated *Salmonella* strains can be employed as mucosally-delivered vaccines or as “reagent strains” to achieve safe, high-yield production of purified antigens for manufacture of parenteral (conjugate) vaccines. A *Salmonella* surface antigen that has generated

## Author Summary

*Salmonella enterica* serovar Paratyphi A is a pathogen that causes a systemic disease that is marked by serious complications and, if untreated, high mortality. The study of *S. Paratyphi A* pathogenesis and vaccine development has been extremely challenging since *S. Paratyphi A* is human host-restricted and no appropriate animal model exists. Since there is currently no licensed vaccine to prevent paratyphoid fever caused by this organism, our study represents a pioneering attempt to develop and refine a vaccine against *S. Paratyphi A*. We employed live attenuated strains which allow *in vivo* presentation of bacterial antigens via the natural route of infection, without the complications associated with antigen production and purification for subunit vaccines. For determining protective immunity against infection, we developed a mouse model that allowed evaluation of vaccine efficacy. We used our system to examine the protective capacity of a major *Salmonella* antigen, the flagellum. Due to its unique immunogenic properties, the flagellum is considered a major immune mediator, but its role in protection is controversial. We clearly show that cell-associated flagellar protein, presented by mucosally administered attenuated bacterial live vaccines, provides superior protection when compared to strains exporting FliC monomers, and we discuss possible mechanisms of immunity.

renewed interest in the role that it may play in protection is the flagellum. Flagella mediate intestinal epithelial and macrophage inflammation following infection and contribute to early host innate immune responses against *Salmonella* [12]. Flagellin (FliC), the monomer of flagellar filaments that induces these effects, is being incorporated into fusion proteins linked to otherwise poorly immunogenic antigens and haptens, providing adjuvant activity to enhance immune responses to those moieties [13–15].

The flagellum is a complex motility organelle composed of >20 different proteins that form a basal body, hook, filament and an export system. The major extracellular part of the flagellum comprises ~20,000 FliC monomers that are exported and assembled at the terminus of a growing filament. Between the hook and filament is a short junction formed by two hook-associated proteins, FlgK and FlgL [16,17]. *S. Typhimurium* mutants defective in FlgK or FlgL synthesize FliC monomers that do not polymerize and are released into the culture medium [17]. A capping structure of five FliD molecules at the end of the filament also promotes FliC polymerization [16,18,19]. Deletion of *fliD* in *S. Typhimurium* incapacitates the ability of transported FliC to polymerize [20,21].

Integral to our efforts to develop a *S. Paratyphi A* vaccine, we addressed the role of flagella as a potential protective antigen by comparing cell-associated flagella with exported flagellin subunits expressed by attenuated strains. Mutants were constructed with deletions in *fliD* or *flgK*, resulting in export of unpolymerized FliC, without impairing its overall expression. These strains allowed us to investigate whether expression of FliC as cell-attached flagellin filaments versus exported monomers, would influence the immune response or protection elicited by these live vaccines.

## Materials and Methods

### Ethics statement

All animal experiments carried out in this work were approved by the University of Maryland Baltimore Office of Animal Welfare

Assurance (OAWA), under approved Animal Use Protocol 0409006.

## Bacterial strains, media and growth conditions

*S. Paratyphi A* wild-type and mutant strains (Table 1) were propagated on animal product-free LB Lennox medium (Athena ES, Baltimore, MD). Lennox agar plates were prepared by addition of 1.5% agar (Difco, BD, Franklin Lakes, NJ). Guanine (0.001% v/v) was added for  $\Delta$ *guaBA* mutant strains. Liquid cultures were incubated at 37°C, 250 rpm, at a ratio of 1:10–1:20 vol:vol medium:flask (high-aeration conditions). For low-aeration growth conditions, the flasks were filled to 75% of their volume with the medium, and shaken at 80 rpm. Time course experiments in liquid culture were seeded with an overnight culture, inoculated to 0.01 OD<sub>600</sub>; samples were removed at regular intervals for determining culture turbidity at OD<sub>600</sub> or plating. For each growth experiment, two flasks were cultured per strain, and each experiment was performed twice. Swimming and swarming assays were carried out on fresh Lennox plates containing 0.3% and 0.5–0.7% agar, respectively. Glucose was added to a final concentration of 0.5% for swarm plates. The swim plates were inoculated by stabbing the center with bacteria harvested from 1.5% Lennox plates. The swarm plates were inoculated by pipetting a 10- $\mu$ l fresh culture, grown in liquid Lennox media to 0.5–0.6 OD<sub>600</sub>, onto the surface of the center of the agar plate. All motility experiments were performed in triplicates and repeated at least twice. Swim and swarm ability are expressed as the radius of the mobility zone; for no swim, the radius of growth was >1 mm and for no swam, 10 mm.

## Mutagenesis

Deletion of *fliD* and *flgK* genes was performed by  $\lambda$  Red-mediated mutagenesis [22] essentially as described [23]. Primers (listed in Table 2) were designed to replace most of the gene of interest with a kanamycin resistance cassette flanked by the Flippase Recombination Targets, FRTs. The kanamycin cassette was later deleted via  $\lambda$  Red recombinase, leaving an FRT scar sequence.

## SDS-PAGE and western blot analyses

Bacterial protein samples were normalized as follows. Cell pellets were washed in 0.125 M Tris-HCl, pH 6.8, brought to 10

**Table 1.** *Salmonella* Paratyphi A strains and their relevant characteristics.

Strain	description	Source
ATCC 9150	WT	CVD-Baltimore collection
Q28b	Clinical isolate	CVD-Baltimore collection, isolated in Mali
EAR 6473	Clinical isolate	CVD-Baltimore collection, isolated in Chile
15.067	Clinical isolate	CVD-Baltimore collection, isolated in Chile
CVD 1901	ATCC 9150 $\Delta$ <i>guaBA</i>	Levine MM, unpublished
CVD 1902	CVD 1901 $\Delta$ <i>clpX</i>	Levine MM, unpublished
9150D	ATCC 9150 $\Delta$ <i>fliD</i>	This study
9150K	ATCC 9150 $\Delta$ <i>flgK</i>	This study
CVD1901D	CVD 1901 $\Delta$ <i>fliD</i>	This study
CVD1901K	CVD 1901 $\Delta$ <i>flgK</i>	This study

doi:10.1371/journal.pntd.0001373.t001

**Table 2.** Mutagenesis oligonucleotides sequence.

Designation	Use*	Sequence (5' to 3')**
PCR1-5FRT-aph	Km <sup>R</sup> cassette	<u>gaattc</u> gtagcGCTGGAGCTGCTTCGAAGTTC
PCR1-3FRT-aph	Km <sup>R</sup> cassette	ctcgagTTCGGGGATCCGTCGACCTGCAGTTC
PCR2-5FliD	<i>fliD</i> deletion	<u>gaattc</u> TCACGCACACGCTGCAGG
PCR2-5FliD-rev	<i>fliD</i> deletion	<u>gctagc</u> ACCTAATGATGAAATGAAGCCATGC
PCR3-3FliD	<i>fliD</i> deletion	<u>gaattc</u> GCTATGAACAAGTCTGATAACAGAGGT
PCR3-3FliD-rev	<i>fliD</i> deletion	ctcgagTTAACGAGAACTCTGGAAAGATGCTTTC GGTGAATCTGC
PCR4-5FlgJ	<i>flgK</i> deletion	<u>gaattc</u> GGCGAACCCAGCTATAACGTATTTGGCG
PCR4-3FlgJ	<i>flgK</i> deletion	<u>gctagc</u> ATTAATCAAGCTGGACATGATGGTTCC
PCR5-5FlgL	<i>flgK</i> deletion	<u>agatct</u> GCGTTACTGAATATTCGCTAAAGGAGAAG
PCR5-3FlgL	<i>flgK</i> deletion	ctcgagCGTATGGCCAATTACCATCGTGCCTGGC

\*Km<sup>R</sup>, Kanamycin resistance gene.

\*\*Restriction endonuclease cleavage sites are underlined. For PCR1, *EcoRI*, *NheI* and *XhoI*; PCR2 and PCR 4, *EcoRI* and *NheI*; PCR3, *BamHI* and *XhoI*; PCR5, *BglII* and *XhoI*.  
doi:10.1371/journal.pntd.0001373.t002

OD<sub>600</sub> in the same buffer and diluted 1:3 with Laemmli sample buffer (Bio-Rad Laboratories, Hercules, CA). Supernatants were brought to the equivalent lowest OD<sub>600</sub> culture per experiment, by addition of 0.125 M Tris-HCl, pH 6.8, and diluted 1:1 with Laemmli buffer. The protein samples were boiled for 10 min, and 10- $\mu$ l aliquots were loaded onto 10% SDS-PAGE gels. For anti-FliC blots, monoclonal antibodies (BioVeris, Gaithersburg, MD) diluted 1:1000 were used for 1 h incubation. Detection was performed with secondary peroxidase-labeled goat anti-mouse IgG (KPL, Gaithersburg, MD), followed by application of the ECL PLUS Western blotting detection system (GE Healthcare, Buckinghamshire, UK). Coomassie blue-stained gels and developed blots were scanned with a V700 Photo EPSON Scan (digital ICE technologies) using SilverFast SE imaging software (LaserSoft Imaging, Sarasota, FL), and quantitated with QuantityOne software (Bio-Rad).

#### Preparation of *S. Paratyphi A* flagella protein standard

*S. Paratyphi A* FliC was prepared from strain CVD 1902 using the shearing. CVD 1902 was chosen for purification of flagella for two reasons. First, it was genetically engineered from the attenuated strain CVD 1901 to hyper-express flagellin by deletion of the *clpX* gene (Table 1), which together with *clpP* encodes the ClpXP ATP-dependent protease that degrades the master flagella positive regulator complex FlhD/FlhC, resulting in large amounts of flagella being over-produced [24]. Second, it is an attenuated strain and as such does not pose an occupational risk when cultured in large volumes for antigen purification.

Bacterial cultures were grown overnight under low aeration conditions in 2-liter flasks containing Lennox broth supplemented with guanine. Cell pellets were washed and resuspended in PBS, and sheared for 3 min at high speed in a Waring laboratory blender. The sheared suspension was centrifuged twice at 7,000 $\times$ g for 10 min, and the supernatant was collected and centrifuged at 100,000 $\times$ g for 3 h to pellet the filaments. The pellet was suspended in saline at 4°C overnight, centrifuged at 7,000 $\times$ g, and the clear supernatant containing flagellar filaments was transferred to a new tube. Protein concentration was determined with the BCA assay (Pierce, Rockford, IL). Purity was assessed by SDS-PAGE and Coomassie blue staining. The amount of contaminating LPS was quantified using the resorcinol sulfuric acid assay [25] using a standard curve generated with purified *S.*

*Paratyphi A* LPS. This FliC preparation was determined to be 98.3% pure.

#### Ultrafiltration

UF membranes with different *Mr* cut-offs were used for gradient separation of flagellin monomers from purified filaments. Supernatants collected from bacterial cultures grown under high-aeration conditions and containing flagellin monomers and/or sheared flagella, were first normalized to equal concentrations of FliC by passing supernatants through a 30-kDa cut-off Amicon membrane (Millipore, Billerica, MA). The concentrated retentants were then passed through a 100-kDa cut-off Amicon membrane. The resulting filtrates were further passed through an additional 30-kDa membrane.

#### Transmission electron microscopy

Bacteria collected from swarm colonies were suspended in PBS to an OD<sub>600</sub> of 1.0 and were incubated with 300 mesh Formvar coated copper grids (Electron Microscopy Services, Hatfield, PA) for 20 min. Grids were gently blotted and placed on 50  $\mu$ l drops of 2% ammonium molybdate (Sigma Aldrich, St. Louis, MO) for 2 min. After air-drying, grids were observed with a JEOL electron microscope JEM-1200EX (JEOL, Tokyo, Japan).

#### Mice housing and handling

For all experiments, 6 week-old female BALB/c mice were purchased from Charles River Breeding Laboratory Inc. (Wilmington, MA) and maintained in a biohazard animal facility. Anesthesia (isoflurane dispensed through a precision vaporizer) was used for blood collection from the retro-orbital plexus. All studies were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Maryland Baltimore School of Medicine, and conducted in accordance with NIH guidelines [23].

#### Mice LD50

For assessment of virulence, the hog gastric mucin assay was used [26]. Mice were injected by the intraperitoneal route (i.p.) with increasing 10-fold dilutions of bacteria; bacteria were harvested from overnight Lennox plates and suspended in PBS mixed with 10% (wt/v) Difco hog gastric mucin (Becton-Dickinson, Sparks, MD) to a final volume of 0.5 ml per mouse.

Groups of six mice per dose per strain were tested. Mice were observed twice daily for 3 days for mortality or any signs of significant morbidity (ruffled fur, weight loss of 20% or more, collapse, difficulty breathing or severe dehydration), and those showing the above signs were euthanized according to IACUC directives. 72 h post-challenge, surviving mice were euthanized using CO<sub>2</sub> asphyxiation followed by cervical dislocation. LD<sub>50</sub> values were calculated by logistic regression analysis.

### Mucosal immunization and challenge

Fresh vegetative cultures of CVD 1901, CVD 1901D or CVD 1901K were pelleted, washed with PBS, and brought to a final concentration of  $\sim 10^{11}$  cfu/ml. 10- $\mu$ l aliquots were applied intranasally on day 0, 14, and 28 to mice (5  $\mu$ l/nostril,  $\sim 10^9$  cfu per mouse; 10–15 mice per group). A group immunized with PBS served as a negative control. Blood samples were collected prior to and after immunization and sera were stored at  $-70^\circ\text{C}$ . Mice were challenged on day 56 with  $3.3 \times 10^5$  cfu per mouse of wild-type ATCC 9150 *S. Paratyphi A*, freshly prepared as described above for the LD<sub>50</sub> studies. Iron (8  $\mu$ l of 5% ammonium iron (III) citrate to 1 ml of mucin) was added to the bacterial suspension to increase virulence [27]. Following the challenge, mice were monitored every 6 h for 72 h for mortality or any signs of significant morbidity.

### ELISA

Total IgG antibodies and IgG subclasses against *S. Paratyphi A* flagella were determined by ELISA as previously described [28]. Briefly, 96-well plates were coated with *S. Paratyphi A* flagella (5  $\mu$ g/well) or LPS (10  $\mu$ g/ml). Samples were diluted in 10% dried milk in PBS containing 0.05% Tween 20 (PBSTM) and tested in duplicates. Specific antibodies were detected using HRP-labeled goat anti-mouse IgG, IgG1 and IgG2 (KPL Inc. Gaithersburg, MD) diluted in PBSTM followed by TMB Microwell Peroxidase Substrate solution (KPL). Titers were calculated by interpolation in a standard curve as the inverse of the dilution that produces an OD value of 0.2 above the blank (ELISA units/ml).

### Bactericidal assay

Bactericidal activity was assessed by a complement-mediated lysis of *S. Paratyphi A* using sera from immunized mice. Fresh vegetative wild-type ATCC 9150 (flagellated) or 9150K (non-flagellated) bacterial suspensions ( $10^6$  cfu/ml) were mixed with 30% guinea pig complement (Sigma-Aldrich, St. Louis, MO), added (1:1) to heat-inactivated ( $56^\circ\text{C}$ , 20 min) serially-diluted mouse sera, and incubated for 1 h at  $37^\circ\text{C}$ . Following incubation, bacteria were counted by plating. End point titers were defined as the last dilution that induced a  $\geq 50\%$  reduction in the number of bacteria incubated with complement alone without addition of serum.

### Opsonophagocytosis

Antibody-mediated bacterial uptake by macrophages was measured by seeding J774A.1 cells into 24-well microdilution plates and growing in DMEM supplemented with 5% FCS at  $37^\circ\text{C}$  with 5% CO<sub>2</sub> to a confluent layer ( $2 \times 10^5$  cells/well). Fresh vegetative wild-type ATCC 9150 bacteria were incubated with heat inactivated mouse serum (10% in PBS) for 30 min on ice, then added to the cell monolayer at a ratio of 1:1. Following centrifugation (100 $\times$ g, 10 min), the microdilution plate containing the monolayer and opsonized bacteria was incubated at  $37^\circ\text{C}$  with 5% CO<sub>2</sub> for 30–45 min. External bacteria were removed by replacing the media with fresh media containing 100  $\mu$ g/ml

gentamicin, incubating for 30–45 min, followed by three PBS washes. The cells were lysed with 0.5% Triton x-100 and internalized bacteria were counted by plating.

### Statistical analysis

LD<sub>50</sub> was estimated by logistic regression analysis. Continuous variables were compared among the groups using Kruskal-Wallis analysis of variance. Proportions in two groups were compared using the Fisher's exact test. Two-sided *p*-values  $< 0.05$  and one-sided *p*-values  $< 0.025$  were considered statistically significant.

## Results

### Selection of a parental *S. Paratyphi A* strain for developing attenuated vaccines


Four *S. Paratyphi A* wild-type strains were compared for growth rate, bacterial cell yield and ability to express FliC, including American Type Culture Collection strain ATCC 9150 and three clinical isolates Q82b (Mali), EAR6473 (Chile) and 15.067 (Chile). No significant differences in growth rate (Fig. 1A) or overall protein electrophoretic profiles (Fig. 1C) were observed among the strains, but ATCC 9150 consistently reached the highest cell yield when grown in rich liquid medium (Fig. 1B). FliC was a major component of the secretomes of all four strains (Fig. 1C, middle panel). The high amounts of flagellar protein found in the supernatants are a consequence of shear forces acting upon the cells during growth in shake flasks, causing filament shearing from the cell surface. Among the four strains, the Chilean isolate 15.067 expressed lower levels of FliC (Fig. 1C, lower panel).

To compare flagellar protein expression further, "swim" and "swarm" motilities were tested, each providing evidence of flagella functionality [29]. Swimming is assayed by growing the bacteria on semisolid medium (0.2–0.4% agar) where bacterial cells swim through water-filled channels in the agar, whereas swarming is observed following inoculation on the surface of solid medium (0.5–0.8% agar). Notably, swarming is associated with greater flagella expression than swimming [29]. In accordance with FliC expression (Fig. 1C), strain 15.067 had reduced motility (Fig. 1D).

We next tested whether variations of flagellar expression affect virulence in mice. Since *S. Paratyphi A* is avirulent in mice when administered orally or intranasally (i.n.), we adopted a mouse model used for *S. Typhi* (another human host-restricted pathogen) to determine LD<sub>50</sub>, in which bacteria are suspended in hog gastric mucin prior to intraperitoneal (i.p.) injection of BALB/c mice. This model has been used to assess the attenuation of candidate oral *S. Typhi* vaccines pre-clinically [26,30] and reasonably predicted responses of humans given those strains in Phase I trials [31,32]. Accordingly, young mice were injected i.p. with 10-fold dilutions of bacteria in 10% (w:v) hog gastric mucin. ATCC 9150 was the most virulent, with an LD<sub>50</sub> value of 52 cfu/mouse, while strains Q82b, EAR6473 and 15.067 exhibited LD<sub>50</sub> values of 846, 199 and 692 cfu/mouse, respectively (Fig. 1E). ATCC 9150, with its excellent growth characteristics, copious flagella production and high virulence in mice, was therefore selected as the wild-type parent for construction of our vaccine candidates; the available genomic sequence of ATCC 9150 provided another rationale for using this strain [33].

### Deletion of *fliD* or *flgK* allows flagellin export

To export flagellin as monomers, we targeted two chromosomal loci, FliD (flagellar cap protein) and FlgK (a hook-filament junction protein), shown in *S. Typhimurium* to encode hook-associated proteins [17,20,34]. To assure the safety of our candidate strains, we first introduced a deletion in the chromo-



**Figure 1. ATCC 9150 is highly culturable, expresses flagella moderately, and is highly virulent.** (A) Growth curves of four *S. Paratyphi A* isolates cultured on Lennox medium at 37°C under high aeration (250 rpm, 1:10 medium:flask volume). (B) Final cell yields were recorded at time point of 8 h (t=8) by performing live counts. Average yields from two independent experiments are shown. (C) Equivalent cell pellets and supernatants from t=8 were analysed by SDS-PAGE and stained with Coomassie (upper panels) or subjected to Western blot analysis with anti-FliC antibody (middle), along with *S. Paratyphi A* FliC standard (100 μg). Estimation of FliC quantity was performed on the blots with Bio-Rad QuantityOne (lower). (D) Swim (0.3% agar) and swarm (0.7%) plates, following 8 h incubation at 37°C. (E) BALB/c mice were injected i.p. with 4 *S. Paratyphi A* isolates. Bacteria were collected from Lennox plates incubated at 37°C over-night, diluted in PBS, and mixed with hog gastric mucin. Groups of naïve BALB/c mice, 6 mice per group were challenged and monitored twice daily for three days. Data represent percent cumulative survival curves. doi:10.1371/journal.pntd.0001373.g001

somal *guaBA* operon of ATCC 9150, which encodes two essential enzymes, inosine monophosphate dehydrogenase (GuaB) and guanine monophosphate synthetase (GuaA), involved in the *de novo* guanine nucleotide biosynthesis pathway. Resulting strain CVD 1901 was then further deleted for *fliD* (yielding CVD 1901D) or *flgK* (CVD 1901K). The *fliD* or *flgK* deletions were also introduced into ATCC 9150, leading to 9150D and 9150K.

ATCC 9150 and the resulting five isogenic strains possessed indistinguishable growth rates when cultured under high aeration in appropriately supplemented rich liquid medium (data not shown). Thus, neither the *guaBA*, *fliD* or *flgK* mutations impaired growth, although bacterial cell yields were somewhat lower compared to ATCC 9150 (Fig. 2A top panel). As expected, analysis of secreted protein confirmed that higher FliC levels were found in supernatants of the  $\Delta fliD$  and  $\Delta flgK$  mutants compared to supernatants from their parental strains (Fig. 2A lower panel).


Differences in FliC expression between the *fliD* and *flgK* mutants and their parents were pronounced when bacteria were propagated as stationary broth cultures (low-aeration) where shear forces acting upon the cells are much lower. Under these conditions, no free FliC was observed in supernatants of either parental strain, yet FliC was observed in supernatants of the *fliD* and *flgK* mutant cultures were as high as when grown under aerated conditions (shown for CVD 1901 and derived mutants, Fig. 2B). Immunoblotting with anti-FliC under low-aeration growth showed that the parental strain retained most flagella on the bacterial cells. In contrast, the mutants exhibited almost undetectable levels of FliC on the cell surface; CVD 1901D showed some residual FliC, while none was detected on the surface of CVD 1901K (Fig. 2C).

*fliD* and *flgK* deletion mutants differ in export of flagellin monomers

Export of FliC from the mutants was elucidated by a three-step characterization (Fig. 3A schema), using serial ultrafiltration (UF) membranes. First, conditioned media of CVD 1901, CVD 1901D and CVD 1901K cultures were adjusted to equivalent FliC concentrations using 30-kDa cutoff UF (Fig. 3A upper gel). Then, 100-kDa (Fig. 3A middle gel) followed by 30-kDa cutoff membranes allowed separation of monomeric from polymeric flagellin. Following the final 30-kDa passage, CVD 1901K supernatant contained the highest amount of flagellin, with less in the CVD 1901D supernatant and almost none in concentrate of the parental CVD 1901 strain (Fig. 3A lower). Thus, flagellin molecules in supernatants from cultures of the *fliD* and *flgK* mutants are in the unassembled form. However, in accordance with the results shown in Fig. 2C, some flagellin expressed by the CVD 1901D mutant is cell-associated, sheared off the cell surface during growth, and retained within the 100-kDa filter. As a control, all culture supernatants were heat-treated to dissociate the polymeric flagella and indeed some FliC was observed in the filtrate of the parental CVD 1901 strain following the 100-kDa UF (Fig. 3A middle and lower).

Second, comparing flagella functionality revealed identical swim and swarm diameters (% of plate) for ATCC 9150 versus CVD 1901; 39% versus 43% for swim and 45% versus 69% for swarm, respectively (Fig. 3B). Strains 9150D and CVD 1901D showed only swimming motility with a diameter of 11% and no swarming, while 9150K and CVD 1901K showed neither swim nor swarm motility. Decreasing the agar concentration in the swarming plates allowed swarming of the  $\Delta fliD$  mutants, while the  $\Delta flgK$  mutants remained non-motile (Fig. 3B). Finally, bacterial samples from the





**Figure 2. *S. Paratyphi A*  $\Delta$ *fliD* and  $\Delta$ *flgK* mutants shade FliC to culture supernatant.** ATCC 9150 and five derivative mutants were grown on Lennox medium under high aeration. (A) Cell yields (upper panel) and Coomassie-stained SDS-PAGE (lower) of culture supernatants following 8 h of growth. (B) Cell yields and SDS-PAGE of supernatants from cultures grown over-night under low-aeration. (C) SDS-PAGE (upper), anti-FliC western blot (middle) and FliC quantitation (lower) of cell pellets from cultures grown over-night under low-aeration.

doi:10.1371/journal.pntd.0001373.g002

0.7% swarm plates were examined by electron microscopy (EM). The negative stained bacterial cell images establish that the  $\Delta$ *flgK* mutant is completely devoid of surface flagella, while the  $\Delta$ *fliD* mutant carries one or two filaments (Fig. 3C).

#### $\Delta$ *fliD* and $\Delta$ *flgK* mutants exhibit similar virulence to their parental strains

Virulence of the mutants was compared to wild-type ATCC 9150 by inoculating 6 week-old mice i.p. with bacteria suspended in hog gastric mucin. An LD<sub>50</sub> value of 8.8 bacteria per mouse was calculated for the wild-type (Fig. 4). In contrast, CVD 1901 showed an LD<sub>50</sub> of 3.0 × 10<sup>7</sup> cfu/mouse. The LD<sub>50</sub>s for 9150D, 9150K, CVD 1901D and CVD 1901K were 17, 49, 3.4 × 10<sup>6</sup> and 2.0 × 10<sup>7</sup> cfu/mouse, respectively (Fig. 4). These results show clear attenuation only for strains harboring the *guaBA* deletion. Deletion of either *fliD* or *flgK* from ATCC 9150 attenuated the resulting strain by only half a log and did not work synergistically with the *guaBA* deletion. Whereas deletion of *flgK* or *fliD* in *S. Paratyphi A* did not alter bacterial virulence in this model, these mutations may nevertheless influence the protection conferred by vaccine strains also deleted in *guaBA*. Accordingly, we examined the ability of these mutants to protect against a *S. Paratyphi A* lethal challenge.

#### A live attenuated strain provides superior protection if it has attached flagella rather than exporting flagellin monomers

Mice were immunized i.n. with ~1 × 10<sup>9</sup> cfu of CVD 1901, CVD 1901D or CVD 1901K on days 0, 14 and 28. Control mice

received PBS. The i.n. route was chosen based on the robust immunity [35,36] and protection [37] induced by attenuated *S. Typhi* administered by this route. Three weeks after the last immunization, mice were challenged with a lethal dose of wild-type ATCC 9150 (3.3 × 10<sup>5</sup> cfu/mouse plus iron, see Materials and Methods). All control mice succumbed within 24 hours post-challenge (Table 3). The vaccine strains differed in their protective capacity, with CVD 1901 conferring significantly superior protection compared to CVD 1901D or 1901K.

Serum IgG antibodies against FliC and LPS rose progressively after each immunization (Fig. 5A), reaching similar levels for all strains. Unlike CVD 1901 (which expresses many) and CVD 1901D (expresses a few) surface-associated flagella, CVD 1901K is devoid of flagella at the time of administration. Hence, FliC antibodies induced by CVD 1901K represent responses to *de novo* FliC synthesized *in vivo*, rather than antigen present at the time of immunization. The slightly higher titers detected in the mice immunized with CVD 1901D may reflect the combined effect of surface-associated and secreted FliC. Overall, there was no significant correlation between anti-FliC or anti-LPS antibody titers and survival (Fig. 5B), nor a correlation of survival with antibodies to *S. Paratyphi A* outer membrane protein fractions (data not shown). Thus, no serum IgG responses against major *Salmonella* surface antigens correlated with protection in this model.


#### CVD 1901, CVD 1901D and CVD 1901K induce similar levels of anti-FliC IgG2a, whereas the flagellin-exporting mutants induce higher levels of anti-FliC IgG1

Since the overall level of anti-FliC IgG among the immunized groups did not correlate with efficacy, we examined IgG antibody subtypes. While all three vaccine strains induced similar levels of anti-FliC IgG2a antibody, CVD 1901D and CVD 1901K induced strikingly high levels of anti-FliC IgG1, which were 50- and 10-fold higher than those induced by CVD 1901, respectively (Fig. 6A,  $p = 0.012$ ). The IgG2a:IgG1 geometric mean ratios were 1.2, 0.036, and 0.051 for CVD 1901, CVD 1901D, and CVD 1901K respectively, implying that a functional IgG2a-biased response, rather than elevated (and likely competing) IgG1 antibodies, might correlate with enhanced protection (Fig. 6B;  $p = 0.042$ ).

#### Cell-associated flagella of CVD 1901 elicit antibodies with opsonophagocytic rather than complement-mediated bactericidal activity

Noting the differences in anti-FliC IgG subtype antibody responses induced by the different live vaccines, we next studied functional activity of the antibodies. Antibody switching to different IgG subclasses requires T-cell help (T<sub>H</sub>) during antigen priming; the presence of IgG1 reflects T<sub>H</sub>2 subset activity, whereas IgG2a indicates a T<sub>H</sub>1-type response. Since live vaccine carrying cell-associated FliC exhibited higher potency compared with flagellin-secreting strains, we further examined the potential contribution of the T<sub>H</sub>1-associated antibody response induced by these strains in protection against *S. Paratyphi A* challenge. The T<sub>H</sub>1 subset is responsible for many cell-mediated functions and favors the production of IgG2a antibodies with opsonophagocytic capacity that bind to high-affinity Fc receptors on macrophages [38]. These antibodies activate the complement system more readily than IgG1 antibodies [39] and efficiently mediate antibody-dependent cell-mediated cytotoxicity [40].

Complement-mediated antibody killing (bactericidal) of wild-type ATCC 9150 was assessed by incubating bacteria with serial dilutions of heat-inactivated sera from immunized mice to which guinea pig complement was added. Sera from naive mice




**Figure 3.  $\Delta fliD$  and  $\Delta flgK$  mutants differ in their ability to export non-assembled flagellin.** (A) Separation between monomeric and filamentous FliC using serial UF membranes. Supernatants were brought to equivalent FliC concentration using 30-kDa Amicon UF units and compared by a Coomassie-stained SDS-PAGE (upper gel). The concentrated samples, with or without heat treatment (70°C, 30 min), were then run through 100-kDa units and compared again (middle). Filtrates from the previous step were passed through 30-kDa units, and the final concentrates were detected (lower). (B) Swim (0.3% agar) and swarm (0.7, 0.6 and 0.5%) plates were scanned following 8 h incubation, 37°C. (C) EM images of negatively-stained bacteria, collected from swarm plates. For CVD1901D, cells carrying two and a single filament are shown. Numbers indicate the extent of magnification.

doi:10.1371/journal.pntd.0001373.g003

established the background activity. For the three sera sets, analogous bactericidal titers against ATCC 9150 were detected with no significant differences between the groups (Fig. 7A,  $p=0.28$ ). Similar results were obtained when the assay was repeated with the non-flagellated 9150K strain (Fig. 7A,  $p=0.22$ ),

indicating that anti-FliC antibodies do not play a major role of *S. Paratyphi A* complement-mediated killing in this mouse model.

We next examined opsonophagocytic activity using a macrophage culture assay that probes the ability of the sera to facilitate uptake of ATCC 9150. Average numbers of intracellular bacteria



**Figure 4.  $\Delta fliD$  and  $\Delta flgK$  mutations do not impair virulence of *S. Paratyphi A* in mice.** Survival of naïve BALB/c mice infected with different strains of *S. Paratyphi A* at the indicated doses (cfu/mouse). Bacteria were collected from plates, diluted in PBS and mixed with hog gastric mucin. Groups of 6 mice were injected i.p. and monitored twice daily.

doi:10.1371/journal.pntd.0001373.g004

**Table 3. Recorded deaths within immunized mice challenge with a lethal dose\* of *S. Paratyphi A* ATCC 9150 wild-type strain.**

immunization	Mortality	Vaccine efficacy	<i>p</i> value***
PBS	8/8	-	-
CVD 1901	1/10 <sup>a</sup>	90%	0.0002
1901D	8/15 <sup>b</sup>	47%	0.026
1901K	7/10 <sup>c</sup>	30%	0.15
Naïve**	0/5	-	-


\*Challenge dose for 52–54 week old mice was  $3.3 \times 10^5$  cfu,  $0.125 \mu\text{M Fe}^{+2}$  in 10% hog gastric mucin.

\*\*Challenged with mucin but no bacteria.

\*\*\*Compared to PBS, from one-sided Fisher's exact test.

<sup>a</sup>vs<sup>b</sup>,  $p=0.034$  and <sup>a</sup>vs<sup>c</sup>,  $p=0.010$ , one-sided Fisher's exact test.

doi:10.1371/journal.pntd.0001373.t003



**Figure 5. Serum IgG against *S. Paratyphi A* FliC and LPS do not correlate with protection.** (A) Total serum anti-FliC and anti-LPS ELISA antibody titers (geometric means  $\pm$  standard error of the mean) from days  $-2$  (prior to vaccination), 27 (two weeks following first boost) and 42 (two weeks following second boost). *S. Paratyphi A* FliC was extracted from strain CVD 1902. LPS was extracted from strain CVD 1901. (B) Comparison of anti-FliC and anti-LPS total serum IgG titers at day 42 from individual mice. Closed shapes represent mice that succumbed to the challenge. doi:10.1371/journal.pntd.0001373.g005


of 3862, 2383 and 2131 per  $5 \times 10^6$  bacteria per well were recovered for sera from mice immunized with CVD 1901, CVD 1901D, and CVD 1901K, respectively (Fig. 7B), indicating a clear increased uptake for CVD 1901 sera ( $p = 0.0002$ ). These data suggest enhanced anti-FliC antibody-mediated clearance of the organism by phagocytic cells induced by vaccines expressing cell-

associated rather than exported FliC, which might be contributing to the vaccine-induced survival from *S. Paratyphi A* challenge *in vivo*.

**Discussion**


Flagellar protein is highly immunogenic and immunomodulatory via stimulation of TLR5, yet questions remain over its role in mediating protection against *Salmonella* [41–45]. Whereas purified Phase 1 flagella filaments or FliC subunits from *S. Typhimurium* [46] or *S. Paratyphi A* [10] inoculated parenterally protect mice against parenteral challenge with wild-type *Salmonella* of the homologous serovar, equipoise exists over whether flagellar protein contributes to protection when presented by live mucosal or parenteral inactivated whole cell vaccines. Flagellin expression is not needed for live oral *S. Typhimurium* vaccines to protect against wild-type challenge [47], while human studies indicate an important role for cell-associated flagella in the protection conferred by parenteral inactivated whole cell typhoid vaccines. Inactivated whole cell vaccines (most derived from wild-type strain Ty2) that provided superior protection also elicited higher anti-flagellar antibodies [48,49]. Importantly, no efficacy was observed in a large-scale controlled field trial when the inactivated vaccine was based on non-flagellated *S. Typhi* mutant TNM1, derived from strain Ty2 [50], suggesting that inactivated whole cell vaccines must express flagella in order to protect humans [50].

We employed attenuated *S. Paratyphi A* to investigate the protective capacity of the flagellar subunit protein FliC expressed by live mucosal vaccines. Since mucosally-administered live vaccines assure *in vivo* expression and presentation of flagellar antigens in a native form, we engineered *S. Paratyphi A* ATCC 9150 with specific deletions affecting flagella filament biosynthesis. SDS-PAGE and western blotting (Fig. 2A–C), UF fractionation



**Figure 6. Immunization with CVD 1901D and CVD 1901K but not CVD 1901, induces high anti-FliC IgG1.** Subclass distribution of IgG antibodies against *S. Paratyphi A* flagella. (A) Anti-FliC IgG1 and IgG2a titers detected in day 42 sera. (B) The ratio between the antibody subclasses. For (A) and (B), closed shapes represent mice that succumbed to the challenge. doi:10.1371/journal.pntd.0001373.g006





**Figure 7. CVD 1901 cell-associated flagella elicits antibodies with opsonophagocytic rather than complement-mediated bactericidal activity.** (A) Serum-induced killing of ATCC 9150 (flagellated) and 9150K (non-flagellated) bacteria mediated by complement. Sera are from day 42 of the experiment described in Fig. 5. (B) Opsonophagocytic activity of sera withdrawn at day 27 in J774A.1 macrophage against the wild-type ATCC 9150 strain. For (A) and (B), closed shapes represent mice that succumbed to the challenge. doi:10.1371/journal.pntd.0001373.g007

(Fig. 3A), motility assays (Fig. 3B) and EM (Fig. 3C) established the phenotypes of these FliC-exporting mutants. While ATCC 9150 and CVD 1901 almost exclusively produce flagellar protein as polymer filaments, 9150D and CVD 1901D (lacking flagellum cap protein) express only one or two filaments. In contrast, 9150K and CVD 1901K (lacking a flagellar hook-associated protein) are completely devoid of flagella. Studies with *S. Typhimurium* explain why *fliD* mutants carry a few intact flagellum polymers. In  $\Delta$ *fliD* *S. Typhimurium* mutants [17], the tips of the hooks are intact and serve as effective heteronuclei for soluble FliC units to re-associate and form a functional flagellum. A filament already initiated has higher affinity for the newly added monomers, which elongate the single filament rather than form more short filaments.

Our engineered strains mutated in *fliD* or *flgK* but unaltered in growth characteristics or virulence (Fig. 4) provided a uniform background to explore the contribution of flagellar protein to immunity and protection. Mucosal immunization of mice with the live vaccines followed by subsequent i.p. challenge with virulent *S. Paratyphi A* showed prominent differences in the level of protection conferred in the face of a potent challenge that killed 100% of control mice (Table 3). CVD 1901 carrying many intact cell-associated flagella conferred 90% vaccine efficacy ( $p=0.0002$ ), while CVD 1901D with just a few cell-associated flagella provided 47% efficacy ( $p=0.026$ ); CVD 1901K with no attached flagella elicited only 30% efficacy ( $p=0.15$ ). Mortality was significantly lower in CVD 1901 recipients (1/10 mice) than in mice immunized with CVD 1901K (7/10 mice,  $p=0.01$ ) or CVD 1901D (8/15 mice,  $p=0.04$ ). These data indicate an advantage for live mucosal *Salmonella* vaccines having cell-associated FliC filaments.

The serum anti-FliC IgG titer did not correlate with protection. In fact, the less protective live vaccines that export

flagellin subunits actually stimulated slightly higher anti-FliC IgG antibody titers (Fig. 5A–B). However, when we dissected the anti-FliC response we found that while all three vaccine strains induced IgG2a anti-FliC, the flagellin-secreting strains (CVD 1901D and 1901K) induced significantly higher IgG1 anti-FliC titers (Fig. 6,  $p=0.012$ ). IgG1 or IgG2a serum antibody responses in mice imply induction of T<sub>H</sub>2- or T<sub>H</sub>1-type subsets, respectively. Thus, both soluble and cell-associated polymeric FliC evoke T<sub>H</sub>1-directed switching to IgG2a but the IgG1 response is related to context. Whereas strong serum IgG1 anti-FliC responses were elicited by soluble exported FliC, this protein did not induce a strong IgG1-dependent T<sub>H</sub>2 response when presented as a bacterial cell-associated polymer, as observed for CVD 1901. Others have reported that mucosal administration of purified *S. Typhimurium* flagellin elicits a strong T<sub>H</sub>2-type response [51–53], while attached flagella on *S. Typhimurium* induce predominantly a T<sub>H</sub>1-dependent response [53]. Thus, the type of response against *S. Typhimurium* FliC did not seem to be determined by any intrinsic properties of FliC but rather appeared to be influenced by the form in which FliC was encountered, either as a soluble or cell-associated antigen [53]. Both monomeric and polymeric FliC induced T<sub>H</sub>2 responses provided these proteins were intact and not attached to cells, and only FliC on cells induced mainly a T<sub>H</sub>1 response [53]. Similar observations have been shown for *Lactobacillus*-associated and soluble FliC [54], indicating a general mechanism for anti-FliC antibody switching. We document the identical behavior for *S. Paratyphi A* FliC protein. However, our study advances the field since, in contrast to earlier reports, we presented FliC *in vivo* as attached whole flagella or as FliC monomers exported by live bacteria; previously, flagellin monomers or polymers were administered as purified protein.

Although many studies have described the immune responses to FliC, we report an association between a specific IgG subtype and protection. Vaccination with monomeric flagellin-exporting live vaccines induced stronger IgG1 anti-FliC responses but less protection against challenge with virulent *S. Paratyphi A*, suggesting that a pronounced T<sub>H</sub>2 response does not predict functional immunity.

One must ponder why certain specific antibodies elicited following vaccination with whole organisms fail to protect. One possibility is that some antibodies in excess may compete or block specific phagocyte Fc receptors that endocytose or phagocytose antibody-coated microorganisms [55]. Overwhelming Fc receptors may interfere with clearance of the pathogen. An excess of IgG1 anti-FliC antibodies induced by the exported FliC may prevent binding of the IgG2a subtype anti-FliC that is critical for clearing *S. Paratyphi A* infection. Alternatively, certain antibodies that lack relevant biological activity may actually enhance rather than control infection; thus, the high IgG1 anti-FliC may enhance the uptake of bacteria into cells without triggering killing. Antibodies that engage Fc receptors and enhance infection have long been known for *Chlamydia trachomatis* [56].

The T<sub>H</sub>1 subset is responsible for cell-mediated functions such as activation of cytotoxic T cells and production of opsonization-promoting IgG antibodies that bind to high-affinity Fc receptors and interact with the complement system. T<sub>H</sub>1 cells produce IL-2 and IFN- $\gamma$  that promote the differentiation of fully cytotoxic T<sub>C</sub> cells, which are suited to respond to intracellular pathogens. IFN- $\gamma$  is a defining cytokine of the T<sub>H</sub>1 subset and activates macrophages to increase microbicidal activity [57]. IFN- $\gamma$  secretion by T<sub>H</sub>1 cells also induces antibody class switching to IgG classes (IgG2a in the mouse) that support phagocytosis and complement fixation. Finally, in immunized mice most *Salmonella*-specific cells secreting IFN- $\gamma$  are also FliC-specific [46].

Complement-dependent serum bactericidal antibodies [SBA] are one functional serological response in humans exposed to *Salmonella* pathogens or vaccines [58]. Our results show that SBA did not correlate with protection (Fig. 7A). Replacing the

flagellated WT *S. Paratyphi A* ATCC 9150 utilized in the SBA assay with non-flagellated strain 9150K, did not alter SBA titers, indicating that anti-FliC antibodies did not function in this assay or contributed only inconsequentially. SBA must bind antigenic determinants on or very near the bacterial surface so that complement may interact with lipid membrane components. Thus, antibodies directed against flagella may be ineffective as SBA.

By contrast, we found antibodies mediating opsonophagocytic activity to be a useful functional correlate of protection against *S. Paratyphi A* (Fig. 7B), as has also been proposed for invasive nontyphoidal *Salmonella* infections [59]. A difference was observed in the opsonophagocytic activity of sera collected from mice immunized with CVD 1901 versus sera from mice immunized with CVD 1901D or 1901K. Sera from CVD 1901 mice readily mediated uptake of virulent *S. Paratyphi A* by phagocytes.

For every human vaccine for which a correlate of immunity exists [60], the correlate is a serum antibody. Live *Salmonella* vaccines elicit both cell-mediated and antibody responses and our studies shed light on the role of immune responses to flagellar protein elicited by a rationally-attenuated *S. Paratyphi A* live vaccine. In addition, the unpolymerized FliC monomers produced by our engineered strains could be exploited as subunit vaccines or as a platform for engineered FliC-heterologous antigen fusions that might not otherwise be supported within the confines of a polymerized flagellum. An additional byproduct of our research is the demonstration of a small animal model that allows, following mucosal immunization, the efficacy of live *S. Paratyphi A* vaccines to be assessed, including discernment among various candidates.

## Author Contributions

Conceived and designed the experiments: OG JEG ST MML. Performed the experiments: OG DJS. Analyzed the data: OG JEG WCB MFP. Contributed reagents/materials/analysis tools: RS. Wrote the paper: OG JEG ST RS WCB DJS MFP MML.

## References

- Vollaard AM, Ali S, Widjaja S, Asten HA, Visser LG, et al. (2005) Identification of typhoid fever and paratyphoid fever cases at presentation in outpatient clinics in Jakarta, Indonesia. *Trans R Soc Trop Med Hyg* 99: 440–450.
- Ochiai RL, Wang X, von SL, Yang J, Bhutta ZA, et al. (2005) *Salmonella paratyphi A* rates, Asia. *Emerg Infect Dis* 11: 1764–1766.
- Karkey A, Aryjal A, Basnyat B, Baker S (2008) Kathmandu, Nepal: still an enteric fever capital of the world. *J Infect Dev Ctries* 2: 461–465.
- Gupta SK, Medalla F, Omondi MW, Whichard JM, Fields PI, et al. (2008) Laboratory-based surveillance of paratyphoid fever in the United States: travel and antimicrobial resistance. *Clin Infect Dis* 46: 1656–1663.
- Levine MM, Taylor DN, Ferreccio C (1989) Typhoid vaccines come of age. *Pediatr Infect Dis J* 8: 374–381.
- Lin FYC, Ho VA, Khiem HB, Trach DD, Bay PVTTC, et al. (2001) The efficacy of a *Salmonella Typhi* Vi conjugate vaccine in two-to-five-year-old children. *N Eng J Med* 344: 1263–1268.
- Mai NL, Phan VB, Vo AH, Tran CT, Lin FY, et al. (2003) Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. *N Engl J Med* 349: 1390–1391.
- Levine MM, Ferreccio C, Black RE, Lagos R, San MO, et al. (2007) Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by *Salmonella enterica* Serovar Paratyphi B. *Clin Infect Dis* 45 Suppl 1: S24–S28.
- Simanjuntak C, Paleologo F, Punjabi N, Darmowitogo R, Soeprawato, et al. (1991) Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. *Lancet* 338: 1055–1059.
- Ruan P, Xia XP, Sun D, Ojcius DM, Mao YF, et al. (2008) Recombinant *S. Paratyphi A* O and H1a as immunogens for protection of mice from lethal infection with *Salmonella paratyphi A*: implications for rational design of typhoid fever vaccines. *Vaccine* 26: 6639–6644.
- Roland KL, Tinge SA, Kochi SK, Thomas LJ, Killeen KP (2010) Reactogenicity and immunogenicity of live attenuated *Salmonella enterica* serovar Paratyphi A enteric fever vaccine candidates. *Vaccine* 28: 3679–3687.
- Zhang XL, Jeza VT, Pan Q (2008) *Salmonella*: from a human pathogen to a vaccine vector. *Cell Mol Immunol* 5: 91–97.
- Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, et al. (2008) Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. *Vaccine* 26: 201–214.
- Bargieri DY, Leite JA, Lopes SC, Sbrogio-Almeida ME, Braga CJ, et al. (2010) Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of *Plasmodium falciparum* merozoite surface protein-1 and the innate immunity agonist FliC flagellin of *Salmonella typhimurium*. *Vaccine* 28: 2818–2826.
- Treanor JJ, Taylor DN, Tussey L, Hay C, Nolan C, et al. (2010) Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. *Vaccine* 28: 8268–8274.
- Ikeda T, Homma M, Iino T, Asakura S, Kamiya R (1987) Localization and stoichiometry of hook-associated proteins within *Salmonella typhimurium* flagella. *J Bacteriol* 169: 1168–1173.
- Homma M, Kutsukake K, Iino T, Yamaguchi S (1984) Hook-associated proteins essential for flagellar filament formation in *Salmonella typhimurium*. *J Bacteriol* 157: 100–108.
- Ikeda T, Kamiya R, Yamaguchi S (1984) In vitro polymerization of flagellin excreted by a short-flagellum *Salmonella typhimurium* mutant. *J Bacteriol* 159: 787–789.
- Homma M, Iino T, Kutsukake K, Yamaguchi S (1986) In vitro reconstitution of flagellar filaments onto hooks of filamentless mutants of *Salmonella typhimurium* by addition of hook-associated proteins. *Proc Natl Acad Sci U S A* 83: 6169–6173.
- Homma M, Fujita H, Yamaguchi S, Iino T (1984) Excretion of unassembled flagellin by *Salmonella typhimurium* mutants deficient in hook-associated proteins. *J Bacteriol* 159: 1056–1059.
- Vonderviszt F, Imada K, Furukawa Y, Uedaira H, Taniguchi H, et al. (1998) Mechanism of self-association and filament capping by flagellar HAP2. *J Mol Biol* 284: 1399–1416.

22. Datsenko KA, Wanner BL (2000) One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proc Natl Acad Sci U S A* 97: 6640–6645.
23. Galen JE, Wang JY, Chinchilla M, Vindurampulle CJ, Vogel JE, et al. (2010) A new generation of stable, nonantibiotic, low-copy-number plasmids improves immune responses to foreign antigens in *Salmonella enterica* serovar Typhi live vectors. *Infect Immun* 78: 337–347.
24. Tomoyasu T, Takaya A, Isogai E, Yamamoto T (2003) Turnover of FlhD and FlhC, master regulator proteins for *Salmonella* flagellum biogenesis, by the ATP-dependent ClpXP protease. *Mol Microbiol* 48: 443–52.
25. Monsigny M, Petit C, Roche AC (1988) Colorimetric determination of neutral sugars by a resorcinol sulfuric acid micromethod. *Anal Biochem* 175: 525–530.
26. Wang JY, Pasetti MF, Noriega FR, Anderson RJ, Wasserman SS, Galen JE, et al. (2001) Construction, genotypic and phenotypic characterization, and immunogenicity of attenuated  $\Delta$ guaBA *Salmonella enterica* serovar Typhi strain CVD 915. *Infect Immun* 69: 4734–4741.
27. Powell CJ, Jr., DeSett CR, Lowenthal JP, Berman S (1980) The effect of adding iron to mucin on the enhancement of virulence for mice of *Salmonella typhi* strain TY 2. *J Biol Stand* 8: 79–85.
28. Tennant SM, Wang JY, Galen JE, Simon R, Pasetti MF, et al. (2011) Engineering and pre-clinical evaluation of attenuated non-typhoidal *Salmonella* strains serving as live oral vaccines and as reagent strains. *Infect Immun*, In press.
29. Harshey RM, Matsuyama T (1994) Dimorphic transition in *Escherichia coli* and *Salmonella typhimurium*: surface-induced differentiation into hyperflagellate swimmer cells. *Proc Natl Acad Sci U S A* 91: 8631–8635.
30. Hone DM, Harris AM, Chatfield S, Dougan G, Levine MM (1991) Construction of genetically-defined double aro mutants of *Salmonella typhi*. *Vaccine* 9: 810–816.
31. Tacket CO, Hone DM, Losonsky GA, Guers L, Edelman R, et al. (1992) Clinical acceptability and immunogenicity of CVD 908 *Salmonella typhi* vaccine strain. *Vaccine* 10: 443–446.
32. Tacket CO, Sztain MB, Wasserman SS, Losonsky G, Kotloff KL, et al. (2000) Phase 2 clinical trial of attenuated *Salmonella enterica* serovar Typhi oral live vector vaccine CVD 908-*htrA* in U.S. volunteers. *Infect Immun* 68: 1196–1201.
33. McClelland M, Sanderson KE, Clifton SW, Latreille P, Porwollik S, et al. (2004) Comparison of genome degradation in Paratyphi A and Typhi, human-restricted serovars of *Salmonella enterica* that cause typhoid. *Nat Genet* 36: 1268–1274.
34. Gillen KL, Hughes KT (1991) Negative regulatory loci coupling flagellin synthesis to flagellar assembly in *Salmonella typhimurium*. *J Bacteriol* 173: 2301–2310.
35. Pickett TE, Pasetti MF, Galen JE, Sztain MB, Levine MM (2000) *In vivo* characterization of the murine intranasal model for assessing the immunogenicity of attenuated *Salmonella enterica* serovar Typhi strains as live mucosal vaccines and as live vectors. *Infect Immun* 68: 205–213.
36. Galen JE, Gomez-Duarte OG, Losonsky GA, Halpern JL, Lauderbaugh CS, et al. (1997) A murine model of intranasal immunization to assess the immunogenicity of attenuated *Salmonella typhi* live vector vaccines in stimulating serum antibody responses to expressed foreign antigens. *Vaccine* 15: 700–708.
37. Wang JY, Noriega FR, Galen JE, Barry E, Levine MM (2000) Constitutive expression of the Vi polysaccharide capsular antigen in attenuated *Salmonella enterica* serovar Typhi oral vaccine strain CVD 909. *Infect Immun* 68: 4647–4652.
38. Heusser CH, Anderson CL, Grey HM (1977) Receptors for IgG: subclass specificity of receptors on different mouse cell types and the definition of two distinct receptors on a macrophage cell line. *J Exp Med* 145: 1316–1327.
39. Klaus GG, Pepys MB, Kitajima K, Askonas BA (1979) Activation of mouse complement by different classes of mouse antibody. *Immunology* 38: 687–695.
40. Kipps TJ, Parham P, Punt J, Herzenberg LA (1985) Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies. *J Exp Med* 161: 1–17.
41. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, et al. (2001) The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. *Nature* 410: 1099–1103.
42. Feuillet V, Medjane S, Mondor I, Demaria O, Pagni PP, et al. (2006) Involvement of Toll-like receptor 5 in the recognition of flagellated bacteria. *Proc Natl Acad Sci U S A* 103: 12487–12492.
43. Franchi L, Amer A, Body-Malapel M, Kanneganti TD, Ozoren N, et al. (2006) Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1beta in salmonella-infected macrophages. *Nat Immunol* 7: 576–582.
44. Miao EA, Puche-Aranda CM, Dors M, Clark AE, Bader MW, et al. (2006) Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1beta via Ipaf. *Nat Immunol* 7: 569–575.
45. Bobat S, Flores-Langarica A, Hitchcock J, Marshall JL, Kingsley RA, et al. (2011) Soluble flagellin, FlhC, induces an Ag-specific Th2 response, yet promotes T-bet-regulated Th1 clearance of *Salmonella* Typhimurium infection. *Eur J Immunol* 41: 1606–18.
46. McSorley SJ, Cookson BT, Jenkins MK (2000) Characterization of CD4+ T cell responses during natural infection with *Salmonella typhimurium*. *J Immunol* 164: 986–993.
47. Kodama C, Matsui H (2004) *Salmonella* flagellin is not a dominant protective antigen in oral immunization with attenuated live vaccine strains. *Infect Immun* 72: 2449–2451.
48. Levine MM (1994) Typhoid Fever Vaccines. In: Plotkin SA, Mortimer E, Jr., eds. *Vaccines*. Philadelphia: W. B. Saunders. pp 597–633.
49. Ashcroft MT, Nicholson CC, Balwant S, Ritchie JM, Sorvan E, et al. (1967) A seven-year field trial of two typhoid vaccines in Guiana. *Lancet* 2: 1056–1060.
50. Wahdan MH, Sippel JE, Mikhail IA, Rahka AE, Anderson ES, et al. (1975) Controlled field trial of a typhoid vaccine prepared with non-motile mutant of *Salmonella typhi* Ty2. *Bull WHO* 52: 69–73.
51. Didierlaurent A, Ferrero I, Otten LA, Dubois B, Reinhardt M, et al. (2004) Flagellin promotes myeloid differentiation factor 88-dependent development of Th2-type response. *J Immunol* 172: 6922–6930.
52. Honko AN, Mizel SB (2004) Mucosal administration of flagellin induces innate immunity in the mouse lung. *Infect Immun* 72: 6676–6679.
53. Cunningham AF, Khan M, Ball J, Toellner KM, Serre K, et al. (2004) Responses to the soluble flagellar protein FlhC are Th2, while those to FlhD on *Salmonella* are Th1. *Eur J Immunol* 34: 2986–2995.
54. Kajikawa A, Igimi S (2010) Innate and acquired immune responses induced by recombinant *Lactobacillus casei* displaying flagellin-fusion antigen on the cell-surface. *Vaccine* 28: 3409–3415.
55. Nimmerjahn F, Ravetch JV (2008) Fcgamma receptors as regulators of immune responses. *Nat Rev Immunol* 8: 34–47.
56. Peterson EM, Cheng X, Motin VL, de la Maza LM (1997) Effect of immunoglobulin G isotype on the infectivity of *Chlamydia trachomatis* in a mouse model of intravaginal infection. *Infect Immun* 65: 2693–2699.
57. Muotiala A, Makela PH (1993) Role of gamma interferon in late stages of murine salmonellosis. *Infect Immun* 61: 4248–4253.
58. MacLennan CA, Gondwe EN, Msefula CL, Kingsley RA, Thomson NR, et al. (2008) The neglected role of antibody in protection against bacteremia caused by nontyphoidal strains of *Salmonella* in African children. *J Clin Invest* 118: 1553–1562.
59. Gondwe EN, Molyneux ME, Goodall M, Graham SM, Mastroeni P, et al. (2010) Importance of antibody and complement for oxidative burst and killing of invasive nontyphoidal *Salmonella* by blood cells in Africans. *Proc Natl Acad Sci U S A* 107: 3070–3075.
60. Plotkin SA (2010) Correlates of protection induced by vaccination. *Clin Vaccine Immunol* 17: 1055–1065.